iiinova — where your digital self keeps evolving

Kacper A Walentynowicz, PhD @kacperwphd.bsky.social · 07/10/2026

Love it 🙌 transforming the whole field of sequencing

Reposted by Kacper A Walentynowicz, PhD

plasmidsaurus @plasmidsaurus.bsky.social · 06/10/2026

About 22% of cell line use worldwide involves misidentified cell lines (source: ICLAC). Now, every Plasmidsaurus RNA-Seq order includes a cell line identity check. We use SNPs already captured in your RNA-Seq reads to confirm sample identity. For more info: plasmidsaurus.com/technical-no...

131

Kacper A Walentynowicz, PhD @kacperwphd.bsky.social · 02/10/2026

There should be a tutorial how to use it - as it is so different to the older version that people cannot find the information they're lookin for. For me personally it is a downgrade than upgrade - very confusing.

100

Reposted by Kacper A Walentynowicz, PhD

plasmidsaurus @plasmidsaurus.bsky.social · 28/08/2026

You can learn a lot about someone from the way they name a sequencing order 😂 Here are a few that caught our attention in the Plasmidsaurus order queue (shared with permission from the customers who submitted them 🙂).

0122

Reposted by Kacper A Walentynowicz, PhD

Itai Yanai @itaiyanai.bsky.social · 14/08/2026

If you’re letting AI do a review of a manuscript for you, just know that (A) it’s super obvious to anyone reading it, (B) it’s dishonest - as you’re explicitly instructed not to do so, and (C) it’s careless - because you’re uploading someone’s confidential material to an AI app.

1409

Reposted by Kacper A Walentynowicz, PhD

Memorial Sloan Kettering Cancer Center @mskcancercenter.bsky.social · 17/02/2026

After 20 years of fighting a rare blood disease, Maureen joined an MSK trial, led by Dr. Heather Landau. Dr. Karlo Perica explains how #CART therapy re-engineered her immune cells to attack the disease. Just one week after her CAR T cell infusion, Maureen’s blood tests were normal.

052

Reposted by Kacper A Walentynowicz, PhD

Eric Topol @erictopol.bsky.social · 02/02/2026

The time of day for cancer immunotherapy is associated with major outcomes. Early is better. Results from a randomized trial of lung cancer, backs up the importance of our circadian rhythm and immune system www.nature.com/articles/s41...

1025873

Reposted by Kacper A Walentynowicz, PhD

IRB Barcelona @irbbarcelona.org · 18/11/2025

📢 Today we celebrate International Day of LGBTQIA+ People In STEM! 📷 A drop of rainbow” (Lara Barrio): 🔴🟢🔵 With just three fluorescent markers it's possible to generate 7 colour combinations that allow researchers to track multiple cell populations in #Drosophila. #LGBTQSTEMDay #PrideInSTEM 🧪

0228

Reposted by Kacper A Walentynowicz, PhD

The Warsaw Glia Community @warsawgliacomm.bsky.social · 21/07/2025

We're back with another exciting session — this time, spotlight on microglial cells! And wait until you see our star-studded lineup of speakers! Don't miss it — join us and stay at the forefront of the latest research! @soyonhonglab.bsky.social #WGC #GLIA

022

Kacper A Walentynowicz, PhD @kacperwphd.bsky.social · 05/05/2025

I'm excited to share that I've been selected to join the Life Sciences Technology Innovation Fellows Program at Cornell SC Johnson College of Business. The future is bright! @scjohnsoncollege.bsky.social #entrepreneurship #science

eship.cornell.edu

Life Sciences Technology Innovation Fellows Program - Entrepreneurship at Cornell

Read more about BioEntrepreneurship

010

Reposted by Kacper A Walentynowicz, PhD

Eric Topol @erictopol.bsky.social · 05/03/2025

Single-cell RNA sequencing of immune cells for over 1,000 people age 18-97 years. A clock of our immune system aging. Tells us about an individual's response to infection, vaccination, Long Covid. Towards an immunome. www.nature.com/articles/s43...

531667

Reposted by Kacper A Walentynowicz, PhD

European Research Council (ERC) @erc.europa.eu · 26/02/2025

Going to the 2025 #MIT #European #Career #Fair this weekend, & wondering how to #fund your future #research? Visit the 🇪🇺 European Union's stand to find out all about European Research Council's #grants! Info 👉 europa.eu/!M4MWm8 #EURAXESS #Europe #Science #Grant #Funding @mitofficial.bsky.social

04221

Reposted by Kacper A Walentynowicz, PhD

Ruben Sebastian @rubensebas.bsky.social · 11/02/2025

Carisma Therapeutics reports Phase 1 results of CT-0508, an anti-HER2 CAR #macrophage that has already been deprioritized, in advanced/metastatic #HER2 overexpressing solid tumors (14 pts). CAR-M therapy is feasible and well-tolerated. @natmedicine.bsky.social www.nature.com/articles/s41...

nature.com

CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial - Nature Medicine

In a first-in-human phase 1 trial, HER2-specific CAR macrophages were feasible to manufacture and well tolerated, with no dose-limiting toxicities in patients with HER2-overexpressing solid tumors.

101